Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive (ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This biomarker has been extensively studied and is easily assayed by histopathologists but it is not currently accepted...

Descripción completa

Detalles Bibliográficos
Autores principales: Luporsi, Elisabeth, André, Fabrice, Spyratos, Frédérique, Martin, Pierre-Marie, Jacquemier, Jocelyne, Penault-Llorca, Frédérique, Tubiana-Mathieu, Nicole, Sigal-Zafrani, Brigitte, Arnould, Laurent, Gompel, Anne, Egele, Caroline, Poulet, Bruno, Clough, Krishna B., Crouet, Hubert, Fourquet, Alain, Lefranc, Jean-Pierre, Mathelin, Carole, Rouyer, Nicolas, Serin, Daniel, Spielmann, Marc, Haugh, Margaret, Chenard, Marie-Pierre, Brain, Etienne, de Cremoux, Patricia, Bellocq, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332349/
https://www.ncbi.nlm.nih.gov/pubmed/22048814
http://dx.doi.org/10.1007/s10549-011-1837-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332349/
https://www.ncbi.nlm.nih.gov/pubmed/22048814
http://dx.doi.org/10.1007/s10549-011-1837-z

Ejemplares similares